About: OPTiMiSE Optimization of Treatment and Management of Schizophrenia in Europe     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Projekt, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:seeAlso
Description
  • The study is an international multicentric collaborative trial. This study will focus on two goals: optimising current treatments in schizophrenia and explore novel therapeutic options for schizophrenia. The study intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new interventions. It is expected that the project will lead to evidence that is directly applicable to treatment guidelines, and will identify potential mechanisms for new drug development. Objectives: I To test applicability of amisulpride as the first step in a treatment algorithm. II To test guideline recommendation that non-responders to an antipsychotic drug benefit from a switch to an antipsychotic with a different receptor binding profile. III To provide the acceptability and outcome data on the application of clozapine in non-responding patients within the first 10 weeks of their treatment initiation. IV To test if an IT-enabled psychosocial intervention can improve treatment adherence and global functional outcome in symptomatically remitted first-episode schizophrenia patients. V To test whether glutamatergic markers predict response to first and second line treatments. VI To test if a combination of pharmacogenetic, proteomics- and metabolomic markers can provide clinical valuable predictive value. VII To define the nature and prevalence of ’organic’ pathology in patients presenting with a first episode schizophreniform psychosis VIII To determine the extent to which MRI measures at first presentation predict the therapeutic response to subsequent antipsychotic treatment. (en)
  • The study is an international multicentric collaborative trial. This study will focus on two goals: optimising current treatments in schizophrenia and explore novel therapeutic options for schizophrenia. The study intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new interventions. It is expected that the project will lead to evidence that is directly applicable to treatment guidelines, and will identify potential mechanisms for new drug development. Objectives: I To test applicability of amisulpride as the first step in a treatment algorithm. II To test guideline recommendation that non-responders to an antipsychotic drug benefit from a switch to an antipsychotic with a different receptor binding profile. III To provide the acceptability and outcome data on the application of clozapine in non-responding patients within the first 10 weeks of their treatment initiation. IV To test if an IT-enabled psychosocial intervention can improve treatment adherence and global functional outcome in symptomatically remitted first-episode schizophrenia patients. V To test whether glutamatergic markers predict response to first and second line treatments. VI To test if a combination of pharmacogenetic, proteomics- and metabolomic markers can provide clinical valuable predictive value. VII To define the nature and prevalence of ’organic’ pathology in patients presenting with a first episode schizophreniform psychosis VIII To determine the extent to which MRI measures at first presentation predict the therapeutic response to subsequent antipsychotic treatment.
Title
  • OPTiMiSE Optimization of Treatment and Management of Schizophrenia in Europe (en)
  • OPTiMiSE Optimization of Treatment and Management of Schizophrenia in Europe (Optimalizace léčby a postupu léčby schizofrenie v Evropě)
skos:notation
  • 7E12076
http://linked.open...avai/cep/aktivita
http://linked.open...kovaStatniPodpora
http://linked.open...ep/celkoveNaklady
http://linked.open...datumDodatniDoRIV
http://linked.open...i/cep/druhSouteze
http://linked.open...ep/duvernostUdaju
http://linked.open.../cep/fazeProjektu
http://linked.open...ai/cep/hlavniObor
http://linked.open...vai/cep/kategorie
http://linked.open.../cep/klicovaSlova
  • schizophrenia; antipsychotic; treatment response; psychosocial intervention (en)
http://linked.open...ep/partnetrHlavni
http://linked.open...inujicichPrijemcu
http://linked.open...cep/pocetPrijemcu
http://linked.open...ocetSpoluPrijemcu
http://linked.open.../pocetVysledkuRIV
http://linked.open...enychVysledkuVRIV
http://linked.open...lneniVMinulemRoce
http://linked.open.../prideleniPodpory
http://linked.open...iciPoslednihoRoku
http://linked.open...atUdajeProjZameru
http://linked.open...usZobrazovaneFaze
http://linked.open...ai/cep/typPojektu
http://linked.open...ep/ukonceniReseni
http://linked.open.../cep/vedlejsiObor
http://linked.open...ep/zahajeniReseni
http://linked.open...tniCyklusProjektu
http://linked.open...n/vavai/cep/vyzva
http://linked.open.../cep/klicoveSlovo
  • schizophrenia
  • antipsychotic
  • treatment response
is http://linked.open...vavai/cep/projekt of
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 32 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software